Attovia Therapeutics, Inc. (ATTO)Healthcare | Biotechnology | San Carlos, United States | NasdaqGM
14.96 USD
+0.24
(1.630%)
⇧
(Oct. 14, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 5:12 a.m. EDT
The immediate outlook is severely bearish as the stock trades significantly below its 50-day and 200-day averages, indicating a clear downtrend where sellers are in control. Recent price action confirms this weakness, with the share price sliding from highs near $20.83 to close at $16.21, erasing nearly a quarter of its value in just two weeks. The fundamental picture offers no counterweight to this technical breakdown; the company is burning through cash with operating losses exceeding 48%, possesses negative book value, and carries a forward P/E that implies no earnings power. While analysts project a substantial recovery to the mid-$40s, the absence of any dividend income, combined with a deteriorating balance sheet and zero price history to validate the business model, makes this a high-risk speculative vehicle rather than an investment opportunity. |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 3.836 |
| Revenue per Share | 0.437 |
| Market Cap | 682,942,912 |
| Forward P/E | -6.29 |
| Website | https://www.attovia.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.32785386 |
| Address1 | 1,091 Industrial Road |
| Address2 | Suite 310 |
| All Time High | 28.0 |
| All Time Low | 14.23 |
| Average Analyst Rating | 1.4 - Strong Buy |
| Average Daily Volume10 Day | 441,660 |
| Average Daily Volume3 Month | 446,836 |
| Average Volume | 446,836 |
| Average Volume10Days | 441,660 |
| Book Value | -32.117 |
| City | San Carlos |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 14.96 |
| Current Ratio | 9.386 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 15.31 |
| Day Low | 14.345 |
| Debt To Equity | 3.836 |
| Display Name | Attovia Therapeutics |
| Dividend Yield | 0.0 |
| Earnings Timestamp End | 1,794,427,200 |
| Earnings Timestamp Start | 1,794,427,200 |
| Ebitda | -75,251,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -11.035 |
| Enterprise To Revenue | 461.313 |
| Enterprise Value | 830,362,880 |
| Eps Current Year | -3.45 |
| Eps Forward | -2.38 |
| Eps Trailing Twelve Months | -2.77 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 20.218775 |
| Fifty Day Average Change | -5.2587748 |
| Fifty Day Average Change Percent | -0.26009363 |
| Fifty Two Week Change Percent | -32.785385 |
| Fifty Two Week High | 28.0 |
| Fifty Two Week High Change | -13.04 |
| Fifty Two Week High Change Percent | -0.46571428 |
| Fifty Two Week Low | 14.23 |
| Fifty Two Week Low Change | 0.7300005 |
| Fifty Two Week Low Change Percent | 0.05130011 |
| Fifty Two Week Range | 14.23 - 28.0 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,785,936,600,000 |
| Float Shares | 26,261,345 |
| Forward Eps | -2.38 |
| Forward P E | -6.285714 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 44 |
| Fullday Change | 0.23999977 |
| Fullday Change Percent | 1.6304332 |
| Fullday Price | 14.96 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -62,459,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.090459995 |
| Held Percent Institutions | 0.36453 |
| Implied Shares Outstanding | 45,651,262 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,026-08-05 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments. The company's products include ATTO-1310, a novel ATTOBODY-based Fc-fusion protein therapeutic that inhibits IL-31; developed for the treatment of chronic pruritic diseases such as CPUO, high-itch AD, cholestatic pruritus, and CKD-aP; ATTO-2306, an ATTOBODY-based, half-life-extended immunoglobulin G (IgG)-fusion protein therapeutic that inhibits IL-13 and IL-31; developed for the treatment of AD and other immune-mediated skin diseases, such as CSU and PN; and ATTO-1091, a trispecific ATTOBODY-based Fc-fusion protein therapeutic that inhibits TL1A, IL-23, and integrin a4ß7; developed for IBD a chronic immune-mediated condition characterized by persistent inflammation of the gastrointestinal tract, includes ulcerative colitis (UC) and crohn's disease (CD). The company was incorporated in 2022 and is based in San Carlos, California. |
| Long Name | Attovia Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 682,942,912 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_1844489898 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -70,109,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 847,287,422 |
| Number Of Analyst Opinions | 5 |
| Open | 14.51 |
| Operating Cashflow | -67,434,000 |
| Operating Margins | -48.451107 |
| Phone | 510 399 5001 |
| Previous Close | 14.72 |
| Price Eps Current Year | -4.3362317 |
| Price Hint | 2 |
| Price To Book | -0.46579692 |
| Price To Sales Trailing12 Months | 379.41272 |
| Profit Margins | 0.0 |
| Quick Ratio | 9.198 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.4 |
| Region | US |
| Regular Market Change | 0.23999977 |
| Regular Market Change Percent | 1.6304333 |
| Regular Market Day High | 15.31 |
| Regular Market Day Low | 14.345 |
| Regular Market Day Range | 14.345 - 15.31 |
| Regular Market Open | 14.51 |
| Regular Market Previous Close | 14.72 |
| Regular Market Price | 14.96 |
| Regular Market Time | 1,792,008,001 |
| Regular Market Volume | 359,577 |
| Revenue Per Share | 0.437 |
| Sand P52 Week Change | 0.16440773 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 45,651,262 |
| Shares Percent Shares Out | 0.0361 |
| Shares Short | 1,649,612 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 648,541 |
| Short Name | Attovia Therapeutics, Inc. |
| Short Ratio | 4.24 |
| Source Interval | 15 |
| State | CA |
| Symbol | ATTO |
| Target High Price | 52.0 |
| Target Low Price | 30.0 |
| Target Mean Price | 42.2 |
| Target Median Price | 45.0 |
| Total Cash | 115,132,000 |
| Total Cash Per Share | 2.522 |
| Total Debt | 4,326,000 |
| Total Revenue | 1,800,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.77 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 20.218775 |
| Two Hundred Day Average Change | -5.2587748 |
| Two Hundred Day Average Change Percent | -0.26009363 |
| Type Disp | Equity |
| Volume | 359,577 |
| Website | https://www.attovia.com |
| Zip | 94,070 |